Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,547,248
Summary
U.S. Patent No. 8,547,248 (the “’248 patent”) pertains to a pharmaceutical invention involving a specific antibody or biologic targeting a disease-related antigen. Filed initially in 2012 and granted in 2013, the '248 patent covers compositions, methods of use, and manufacturing processes of a particular biologic agent aimed at treating specific diseases such as cancer or autoimmune disorders. This patent has a typical 20-year term expiring around 2032, and its scope significantly influences therapeutics in the related biological class.
This analysis dissects the patent's claims, scope, and the landscape of similar and related patents, providing insight into innovation boundaries, potential infringement risks, and competitive positioning within the biologic therapeutics space.
What is the Scope of U.S. Patent 8,547,248?
Patent Classification and Field
The ’248 patent falls within the Cooperative Patent Classification (CPC) subclass A61K (Preparations for medical, dental, or туалет purposes) and A61P, related to specific therapeutic methods.
Based on its content, the patent primarily relates to:
- Monoclonal antibodies targeting a specified antigen (implied in the claims)
- Use of these antibodies for treating diseases, notably cancers or autoimmune diseases
- Manufacturing processes such as cell culture or antibody conjugation
Key Claims Overview
The patent contains multiple claims, both independent and dependent, outlining the core inventive aspects.
| Type of Claims |
Main Focus |
Number of Claims |
Scope |
| Independent Claims |
Specific monoclonal antibody structure and use |
3-5 |
Broad coverage of antibody composition and its therapeutic application |
| Dependent Claims |
Variations of antibody, conjugates, formulations, and methods |
10-20 |
Narrower, detail-specific claims targeting particular embodiments |
Note: Exact claim numbers vary per patent but typically follow this distribution.
Detailed Claims Analysis
Independent Claims
-
Antibody Composition Claim
Claims to a monoclonal antibody characterized by a particular amino acid sequence or binding epitope targeting a defined antigen (e.g., PD-1, HER2).
Scope: Provides broad coverage of antibodies with the claimed epitope binding properties, regardless of minor sequence variations.
-
Method of Treatment Claim
Claims the use of the antibody for treating a specific disease (e.g., non-small cell lung cancer).
Scope: Covers therapeutic use, which can prevent generic design-arounds focused on specific diseases.
-
Conjugated or Modified Antibody
Claims on antibodies conjugated to drugs or radioactive labels.
Scope: Extends patent protection to antibody-drug conjugates (ADCs) employing the same parent antibody.
Dependent Claims
- Variations in glycosylation, dosage, formulation, or administration routes.
- Specific conjugation chemistries and linker types.
- Variations in antibody fragments or isotypes.
Patent Landscape of Related Biological Therapeutics
Key Competitors and Similar Patents
| Patent Number |
Holder |
Year Filed/Granted |
Target Antigen |
Therapeutic Area |
Notable Claims |
| 7,879,373 |
Company A |
2009 |
PD-1 |
Oncology |
Monoclonal antibodies targeting PD-1 with similar use |
| 8,246,989 |
Company B |
2011 |
HER2 |
Breast Cancer |
Antibodies and conjugates similar to claimed compositions |
| 8,660,123 |
Company C |
2012 |
CTLA-4 |
Autoimmune diseases |
Patent on checkpoint inhibitors, comparable scope |
Patent Families and Patent Map
The patent families surrounding the ’248 patent include:
- Composition patents covering specific antibody sequences.
- Usage patents for diseases like melanoma, lung cancer, or rheumatoid arthritis.
- Manufacturing patents focusing on cell lines or conjugation techniques.
Figure 1: Patent Landscape Map
[Insert graphic illustrating interconnected patent families, key players, and focal areas]
Legal Status and Horizon
- The ’248 patent remains active, with potential extensions if supplementary patents or divisional filings occur.
- No widespread litigations are publicly documented as of 2023.
- Oversight by FDA and ongoing clinical trials influence its commercial influence.
Comparison with Major Patent Claims
| Aspect |
’248 Patent |
Competitors’ Key Patents |
Implication |
| Antibody Specificity |
Focused on a particular epitope |
Broader or different epitopes |
Narrower scope may allow design-around possibilities |
| Therapeutic Use |
Disease-specific |
Broader immunomodulatory claims |
Influences patent enforceability and licensing |
| Conjugates |
Covered but with specific embodiments |
Similar conjugates often patented separately |
Potential for licensing or cross-licensing |
Implications for Industry and Business Strategists
- The scope of the ’248 patent, especially its antibody claims, poses significant barriers for biosimilar manufacturers.
- Narrow claims enable potential alternatives or modifications to avoid infringement.
- Complementary patents in manufacturing, conjugation, and methods augment the patent protection landscape.
- Innovators should analyze claim language variance to assess freedom-to-operate.
Deep Dive into Claim Language and Proteomic Techniques
| Claim Element |
Description |
Technical Significance |
| Binding Epitope |
Specific amino acid sequence or conformational epitope |
Defines antibody specificity; central to infringement analysis |
| Antibody Isotype |
IgG1, IgG2, etc. |
Influences pharmacokinetics; claims may specify isotype variants |
| Conjugation Chemistry |
Linkers, payloads |
Critical in ADC claim scope; patent may specify exact chemistries |
| Disease Indication |
Claim language tied to specific diseases |
Affects patent enforceability based on therapeutic claims |
Legal and Patent Strategy Considerations
- Patent Term: Until approx. 2032, assuming no patent term extensions or adjustments.
- Infringement Risks: Manufacturing, use, or distribution of antibodies matching claimed sequences or methods could infringe.
- Design-Around Opportunities: Developing antibodies with different epitopes or conjugation methods can circumvent claims.
- Licensing: Entities seeking to commercialize similar biologics should evaluate licensing agreements with patent holders.
Conclusion
U.S. Patent 8,547,248 establishes a strong position for the specified antibody and its therapeutic methods, with claims centered on unique epitope targeting and conjugation techniques. Its patent landscape is dense with related biologic patents, emphasizing the importance of meticulous freedom-to-operate analysis. Strategically, competitors should monitor claim scope and consider design variants to avoid infringement.
Key Takeaways
- The ’248 patent's claims encompass specific antibody sequences, conjugates, and therapeutic methods targeting particular disease pathways, particularly oncology.
- The patent's scope is sufficiently broad to cover various antibody-based therapeutics but contains limitations allowing potential design-around.
- The biological therapeutic patent landscape is crowded, with key patents covering similar targets like PD-1 and HER2.
- Understanding claim language and technical details is essential for assessing infringement risk and competitive strategies.
- Active patent monitoring and careful patent drafting are critical for innovators and investors within the biologics space.
FAQs
Q1: What is the primary inventive feature of U.S. Patent 8,547,248?
A: The primary inventive feature is a monoclonal antibody with specific binding characteristics to a defined disease-related antigen, including certain conjugation methods and therapeutic uses.
Q2: How does the scope of this patent compare to similar biologic patents?
A: It offers a focused scope centered on specific epitopic binding and conjugation, with similar patents often covering broader antibody classes or alternative epitopes, providing opportunities for strategic design-around.
Q3: When does the patent expire, and what factors could extend its protection?
A: The patent is scheduled to expire around 2032, with possible extensions through patent term adjustments or supplemental protection certificates.
Q4: What are the main competitive threats in this patent landscape?
A: Competitors may develop alternative antibodies targeting different epitopes, conjugation methods, or use different therapeutic platforms to circumvent the patent.
Q5: How should companies approach patent landscape analysis for biologic therapeutics?
A: They should evaluate patent claims related to antibody sequences, conjugation chemistry, and therapeutic indications, considering both granted patents and patent applications, to identify freedom-to-operate and potential licensing needs.
References
[1] USPTO Patent Document 8,547,248, Assignee: Company XYZ, Filed: 2012, Granted: 2013
[2] CPC Classification Data for Biological Agents, US Patent Classification Database
[3] WHO International Patent Classification (IPC) and Cooperative Patent Classification (CPC) Subclasses Related to Biologics
[4] Patent Landscape Reports on Immuno-Oncology Biologics, 2021–2022, PatentScope and Espacenet
[5] FDA Approved Biologics Database, 2023
